Compugen reports third quarter revenue of $1.9 million and cash position of $86.1 million
Compugen Ltd. reported revenues of approximately $1.9 million for the third quarter ended September 30, 2025, a decrease from $17.1 million in the same period of 2024. Research and development expenses were $5.8 million, down from $6.3 million in the third quarter of 2024. General and administrative expenses were $2.2 million compared to $2.6 million in the previous year. The company reported a net loss of $7.0 million, or $0.07 per basic and diluted share, versus a net profit of $1.3 million, or $0.01 per basic and diluted share, in the third quarter of 2024. As of September 30, 2025, Compugen held $86.1 million in cash, cash equivalents, short-term bank deposits, and marketable securities, with no debt, and expects its cash position to fund operations into the third quarter of 2027. During October 2025, the company sold approximately 0.8 million shares through its ATM facility, raising about $1.6 million. Compugen continues to advance its immuno-oncology pipeline and maintains partnerships with AstraZeneca and Gilead.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO18568) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.